Turnstone Limited Partnership

Ottawa Hospital Research Institute

Sillajen Biotherapeutics, Inc.

Wellstat Biologics Corporation

Robarts Research Institute

Sillajen, Inc.

Celverum Inc.

Avaya Inc.

University of Ottawa

Children's Hospital of Eastern Ontario Research Institute Inc.

Turnstone Biologics Corp.

Mcmaster University

John Cameron Bell

David F Stojdl

Brian D Lichty

Fabrice Le Boeuf

David H Kirn

Jean-Simon Diallo

Carolina Solange Ilkow

Grant McFadden

Rozanne Arulanandam

Caroline Breitbach

Mi-kyung Kim

Yu Kyoung Lee

David Conrad

Harold L Atkins

Anne Moon

Tae-Ho Hwang

David Stojdl

Christopher Brown

Robert Michael Lorence

Christopher John Brown

Laurence A Beaulieu

Raymond Bruce Wallace

Michael Scot Roberts

Byram Bridle

Yonghong Wan

Christopher Hobbs

Steven H Bernstein

Almohanad Alkayyal

Rebecca Auer

Jonathan Pol

Victoria Ann Maher

Briana Livia Rollande Samson

Matthew Y Tang

Michael S Huh

Brian Andrew Keller

Michael F Burgess

Caroline J Breitbach

Harry Atkins

Adrian Pelin

Chantal Lemay

David F Stodjl

Nahum Sonenberg

Cory Batenchuk

Earl G Brown

Fabrice Leboeuf

Ricardo M Marius

Shane B Knowles

Conrad J Heilman, Jr

Mi-Kyung Kim

Grant Mcfadden

Bryam Bridle

Fabrice Robert Le Boeuf

The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.

Modified orthopoxvirus vectors

The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.

MicroRNA-based compositions and methods used in disease treatment

Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.

Oncolytic rhabdovirus expressing IL12

There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.

Non-replicating virus-derived particles and uses thereof

Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.

Methods and compositions for production of vaccina virus

There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.

Vaccine composition

Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.

Compositions and methods for enhancing virus replication

In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.

Engineered synergistic oncolytic viral symbiosis

The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

Methods and compositions for production of vaccinia virus

Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

Oncolytic rhabdovirus

Growing community of inventors

Ottawa, Canada

John Cameron Bell